Meet the mom curing her daughter's incurable disease

When Karen Aiach’s infant daughter Ornella was diagnosed with a fatal genetic disorder, she upended her own life to find a cure. Five years after doctors told her Ornella likely wouldn’t live past adolescence, Karen won approval to put the treatment she developed into clinical trials. Her first subject? Ornella.

This is practically unheard of. Karen isn’t a doctor, and had never worked in medicine. The disease Ornella has–called Sanfillipo syndrome–is so rare that almost no one was trying to cure it. But by raising the money and coordinating researchers from across the globe, she was able to develop a revolutionary treatment. And she did it using gene therapy.

“Some people would say, ‘What is she going to do? If no one has done it before, it’s because it cannot be done.” – Karen Aiach

Right now, there are only three gene therapies on the market in the entire world. First developed in 1988, it’s one of the newer and most cutting edge therapy techniques we have. It involves using a virus to replace faulty genetic code with good genetic code.

Lysogene, the company Karen started, has changed Ornella’s and Karen’s lives. And if it passes clinical trial stage, it could change the lives of Sanfilippo sufferers across the globe–and pave the way for a bold new era of medicine.

Related
Lung cancer drug slashes patients’ risk of death by 51%
Osimertinib, an FDA-approved lung cancer drug, slashes the risk of death for certain patients by 51%, according to new trial results.
The placenta may play a role in the genetic risk of schizophrenia
Researchers at Johns Hopkins have found that genes associated with schizophrenia risk may impact the placenta, not just the brain.
Gain-of-function research is more than just tweaking risky viruses
Gain-of-function experiments in the lab can help researchers get ahead of viruses naturally gaining the ability to infect people in the wild.
Chronic pain can be objectively measured using brain signals
Even though pain is universal and we know it happens in the brain, we’ve never before had a way to objectively measure its intensity.
Do we finally know what causes Alzheimer’s?
The first treatments proven to slow cognitive decline in Alzheimer’s are helping settle a decades-long debate about how the disease starts.
Up Next
Subscribe to Freethink for more great stories